Patent intelligence · US
US 10413566
Thixotropic oxidized cellulose solutions and medical applications thereof
Thixotropic oxidized cellulose solutions and medical applications thereof
Patent details — US 10413566
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 17, 2019
- Expiration
- Sep 12, 2039
- Applicant
- Covidien LP
- Claims
- 12
- CPC classes
- A61K, A61K31/295, A61K31/445, A61K31/714
Quick answer
US 10413566 (Thixotropic oxidized cellulose solutions and medical applications thereof) is held by Covidien LP. Status: granted. Granted Sep 17, 2019. Expires Sep 12, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Covidien LP
- Grant date
- Expiration
- Claims
- 12
- CPC classes
- A61K, A61K31/295, A61K31/445, A61K31/714, A61K31/717, A61K33/20
More from Covidien LP
Related pharmaceutical patents in our USPTO index.
-
US 12364708
Injectable scaffold for treatment of intracranial aneurysms and related technology
granted -
US 12358968
Utilization of CD39 and CD103 for identification of human tumor reactive T cells for treatment of cancer
granted -
US 12336973
Cancer therapeutic compositions and methods targeting DNAse1L3
granted -
US 12329909
Airway management systems for pulmonary disorder treatment
granted -
US 12285397
Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders
granted -
US 12185909
System and method for cleansing segments of a luminal network
granted -
US 12150461
Nicotinamide adenine dinucleotide (NAD) compositions, methods of manufacturing thereof, and methods of use thereof
granted -
US 12144801
Methods and compositions for treatment of epileptic disorders
granted
Related coverage
BBSW AI Solution: Key Insights from the 2026 Event
The BBSW AI Solution event in Foster, USA, promises to unveil critical advancements in AI technology for the pharma industry. Stay tuned for live updates and key takeaways.
BBSW AI Solution 2026: Key Insights and Highlights
The BBSW AI Solution event in 2026 is set to unveil groundbreaking advancements in AI technology. Join us for live coverage and key insights from industry leaders.
Frequently asked questions
What is US patent 10413566?
US 10413566 (Thixotropic oxidized cellulose solutions and medical applications thereof) is held by Covidien LP. Status: granted. Granted Sep 17, 2019. Expires Sep 12, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10413566?
Covidien LP is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 193 pharmaceutical patents for this assignee.
When does US 10413566 expire?
Our index shows an expiration date of Sep 12, 2039 (13 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.